GlobeNewswire

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma

Dela

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors.

With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners.

The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year.

Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have limitations in efficacy or cause harmful side effects, due to systemic estrogen depletion. The novel HSD17B1 inhibitor is the first concept aiming for a local effect in the endometriosis lesions.

 “Forendo Pharma has shown reassuring progress the last year and it is very encouraging to see that they successfully continue to attract new capital", comments Viktor Drvota, CEO of Karolinska Development.

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around

scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com


Bilaga

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E. announces the pricing of a US$250 million re-tap to its 5.875% Senior Notes due 2027.22.1.2020 00:32:00 CETPress release

Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E. announces the pricing of a US$250 million re-tap to its 5.875% Senior Notes due 2027. Luxembourg, January 22, 2020 – Millicom’s wholly-owned subsidiary Telefónica Celular del Paraguay S.A.E, (“the “Company”) announced the pricing of a US$250 million re-tap to its senior unsecured notes due 2027 (“New Notes”), representing an additional issuance of the Company’s outstanding US$300 million 5.875% Senior Notes due 2027 issued on April 5, 2019 (the “Initial Notes”). The New Notes will be treated as a single class with the Initial Notes, and they were priced at 106.375 for an implied yield to maturity of 4.817%. The offering is expected to close on January 28, 2020. The Company intends to use the net proceeds from the offering to repay certain local borrowings, and for general corporate purposes, which could include, in addition to funding operations, distributions to shareholders. The New Notes are being offered only to qualified

Medtronic Named to FORTUNE’s 2020 World’s Most Admired Companies List21.1.2020 16:57:00 CETPress release

Global Leader in Medical Technology Ranks #2 in Industry on Annual List DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) has been named to FORTUNE’s 2020 World’s Most Admired Companies List. The global leader in medical technology landed at #2 in the Medical Products and Equipment industry. “We are honored to be selected by Fortune for this prestigious recognition,” said Omar Ishrak, Medtronic chairman and chief executive officer. “Our 90,000 people around the world strive every day to bring innovative products to market that achieve our longstanding Mission - to alleviate pain, restore health, and extend life. We seek to achieve this Mission responsibly, and we remain committed to being a company worthy of the trust and admiration of our investors, employees and customers.” The annual list measures corporate reputation among the world’s largest companies – the 1,000 largest U.S. companies by revenue, along with non-U.S. companies in Fortune’s Global 500 database that

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement21.1.2020 16:17:00 CETPress release

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECT, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR WHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. By a company announcement dated 19 December 2020, AS PRFoods (hereinafter "PRFoods") informed investors that it was planning an issue of notes. PRFoods hereby notifies that the supervisory board of PRFoods has approved the principal terms and conditions of the note issue and has authorised the management board to issue up to 100,000 secured notes, with the maximum aggregate nominal value of up to EUR 10,000,000, nominal value of EUR 100 per note, interest rate of 6.25% per annum and maturity date on 22 January 2025 (hereinafter the “Notes”). Other than as brought out above, the material terms and conditions of the Notes

C-RAD Web Presentation Year-end Report 201921.1.2020 16:00:00 CETPress release

Presentation of the report for the fiscal year 2019: Date: Friday January 31, 2020 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Year-end Report 2019 Procedure: Please register online through the website: https://attendee.gotowebinar.com/register/5556738657110259724 After your registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RAD C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa Inte

A subsidiary of PRFoods AS obtained an approval to expand fish farming in Sweden.21.1.2020 15:32:00 CETPress release

A subsidiary of PRFoods AS, Överumans Fisk AB obtained an approval to establish an additional fish farm in the Västerbotten region of Sweden. The permit is valid for fish farming and keeping fish over winter. The permit grants the right to use 2400 tonnes of fish feed to farm approx. 2200 tonnes of fish. The permit shall entry into force after the expiry of dispute time and shall be valid for 15 years. “An important part of PRFoods strategy is to expand the volume of fish farming in Finland, Sweden and Estonia. The permit in Sweden allows us to nearly triple the volume of farming in Sweden, and for this, our fish farming management team, led by Margus Rebane, has done outstanding work for many years. Fish from our own farms guarantees that our factories have high-quality and environmentally friendly raw material and we can provide fish products of excellent quality to consumers. The next step for the company is to establish a sustainable fish farming industry in Estonia, which would be

EDHEC-Scientific Beta Research Chair Publication Questions the Existence of a "Green" Factor21.1.2020 14:45:00 CETPress release

Press Release Boston, London, Nice, Paris, Singapore, Tokyo, January 21, 2020 EDHEC-Scientific Beta Research Chair Publication Questions the Existence of a "Green" Factor Study sees no evidence so far to support the existence of such a factor A new publication from the EDHEC-Scientific Beta "Advanced Factor & ESG Investing" research chair, entitled "The DeCarbonisation Factor: A New Academic Fiction?", by Abraham Lioui, Professor of Finance at EDHEC Business School and member of the EDHEC-Scientific Beta Research Chair, examines two recent papers, Cheema-Fox et al. (2019) and Bolton and Kacperczyk (2019), which looked at the financial market implications of firms’ carbon emissions. The Cheema-Fox et al. paper, entitled "Decarbonization Factors," has been widely marketed and often serves to support the usefulness of considering a green factor in the factor allocation menu. Faced with this assertion, Professor Lioui observed that the second paper contradicted the results of the first one